SHAREHOLDER ALERT: Investigation of Biogen Announced by Holzer & Holzer, LLC

November 11, 2020 10:01 AM EST | Source: Holzer & Holzer LLC

Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether Biogen Inc. (NASDAQ: BIIB) ("Biogen" or the "Company") complied with federal securities laws. Trading in Biogen was halted on November 6, 2020, in advance of the Company's meeting with the FDA. On the same day, Bloomberg reported in an article titled "Biogen Alzheimer's Drug Fails to Gain FDA Panel's Backing," that "the outside experts voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show Biogen's drug works." According to the article, the experts "also voted 10 to 0, with 1 undecided, that the positive study shouldn't be considered primary proof the drug works in light of conflicting evidence from a different trial." The price of Biogen's stock fell following the announcement.

If you purchased shares of Biogen and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at mdees@holzerlaw.com or Luke R. Kennedy, Esq. at lkennedy@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:

Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67975

info